Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Other Accumulated Expenses (2016 - 2025)

Ligand Pharmaceuticals' Other Accumulated Expenses history spans 8 years, with the latest figure at $135000.0 for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 89.63% year-over-year to $135000.0; the TTM value through Dec 2025 reached $135000.0, down 89.63%, while the annual FY2025 figure was $135000.0, 89.63% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $135000.0 at Ligand Pharmaceuticals, roughly flat from $135000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.3 million in Q4 2024 and bottomed at $135000.0 in Q3 2025.
  • The 4-year median for Other Accumulated Expenses is $452500.0 (2022), against an average of $565500.0.
  • The largest YoY upside for Other Accumulated Expenses was 89.63% in 2025 against a maximum downside of 89.63% in 2025.
  • A 4-year view of Other Accumulated Expenses shows it stood at $457000.0 in 2022, then surged by 100.44% to $916000.0 in 2023, then surged by 42.14% to $1.3 million in 2024, then tumbled by 89.63% to $135000.0 in 2025.
  • Per Business Quant, the three most recent readings for LGND's Other Accumulated Expenses are $135000.0 (Q4 2025), $135000.0 (Q3 2025), and $1.3 million (Q4 2024).